• News
  • SAN DIEGO
  • BioTech

Mast Therapeutics optimistic after test results

Mast Therapeutics Inc. (NYSE: MSTX), a San Diego-based company working to develop a product for diseases or conditions characterized by impaired blood flow, announced Monday that its lead candidtate demonstrated a statistically significant improvement in numerous parameters of heart function in a placebo-controlled, nonclinical model of chronic heart failure.

The company said the improvements were seen in functions including left ventricular ejection fraction, end-systolic volume, stroke volume and cardiac output. The model tested Mast's MST-188, a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent.

According to Mast, results showed that a single two-hour infusion of MST-188 resulted in improvements that were significant immediately following the full MST-188 administration, and remained significant at one week. In some cases, the improvements were still seen at two weeks following administration.

Dr. Hani N. Sabbah, professor of medicine and director of cardiovascular research at Henry Ford Health System, said the data show that MST-188 improves left ventricular ejection fraction and end-systolic volume, both of which are important indicators of long-term mortality and morbidity in chronic heart failure.

"The durability of response is very encouraging and merits clinical investigation," Sabbah said.

Dr. Santosh Vetticaden, chief medical officer of Mast Therapeutics, called heart failure an area of significant unmet medical need in that it accounts for more than one million hospitalizations every year in the U.S.

"We look forward to discussing these results with heart failure experts and potential partners and mapping our clinical development strategy in this exciting new indication," Vetticaden said.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Mast Therapeutics Inc.

Company Website

12390 El Camino Real Ste., 150
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
MSTX
0.5
  -0.01  
- 1.96%
703,889,000
0.63
0.38

Mast Therapeutics Inc. Executive(s):

Brian Culley

  • Chief Executive Officer

Patrick Keran

  • Chief Operating Officer, President

Brandi Roberts

  • Chief Financial Officer